Pfizer Inc (PFE)
MSN Money Report
Page generated 4/4/2012 10:22 PM Eastern Time
QUOTE DETAIL
After Hours: 22.35 -0.03 / -0.16% Vol. 636,028 |
22.39 -0.16 -0.69% |
---|
Volume | 30.37 Mil | PFE Intraday Chart![Intraday Chart](PFE%20financials_files/chrtsrv.gif) NYSE Exchange 5d 1m 3m 1y 3y 5y 10y Data Source: CSI 10:22 PM ET Quotes delayed 15 minutes |
Avg Daily Volume | 38.28 Mil |
Day's High | 22.45 |
Day's Low | 22.25 |
Open | 22.42 |
Previous Close | 22.54 |
Bid | 22.00 |
Bid Size | 100 |
Ask | 26.99 |
Ask Size | 200 | Current Div. Yield | 3.90 |
52 Week High | 22.80 | Market Cap. | 168.7 Bil |
52 Week Low | 16.63 | Tot. Shares Out. | 7.537 Bil |
Instit. Ownership | 70.5% | Forward P/E | 10.00 |
fyi P/E | 20.40 | Sales | 67.43 Bil |
Earnings/Share | 1.27 | Return on Equity | 10.24 |
Div/Share | 0.88 | Beta | 0.72 |
Last trade (extended hours) 07:01 PM ET
Financial data in U.S. dollars
NEWS & ANALYSIS Seeking Alpha|06:37 PM Associated Press|06:05 PM Associated Press|01:21 PM Associated Press|01:20 PM Bloomberg|12:44 PM Associated Press|11:07 AM Bloomberg|04/03/12 InvestorPlace|04/03/12
| |
OPTIONS
APRIL 21, 2012 CALLSShaded options are in-the-money
APRIL 21, 2012 PUTSShaded options are in-the-money
1 YEAR CHART
![1 Year Chart](PFE%20financials_files/chrtsrv_003.gif)
COMPANY REPORT
Pfizer
Inc. (Pfizer) is a research-based, global biopharmaceutical company.
The Company manages its operations through five segments: Primary Care;
Specialty Care and Oncology; Established Products and Emerging Markets;
Animal Health and Consumer Healthcare, and Nutrition. The Company’s
diversified global healthcare portfolio includes human and animal
biologic and small molecule medicines and vaccines, as well as
nutritional products and consumer healthcare products. Its Animal Health
business unit discovers, develops and sells products for the prevention
and treatment of diseases in livestock and companion animals. On August
1, 2011, it completed the sale of its Capsugel business. In October
2011, it acquired Icagen, Inc. In December 2011, it acquired the
consumer healthcare business of Ferrosan Holding A/S. In December 2011,
it acquired Excaliard Pharmaceuticals, Inc.
STOCK ACTIVITY
Last Price |
22.3850002288818 |
52 Week High |
22.80 |
52 Week Low |
16.63 |
Volume |
30.37 Mil |
Average Daily Volume (13wk) |
38.28 Mil |
50 Day Moving Average |
21.57 |
200 Day Moving Average |
20.04 |
Volatility (beta) |
0.72 |
Detailed quote
Financial data in U.S. dollars
STOCK PRICE HISTORY
| Change | Relative Strength |
Last 3 Months |
2.6% |
40 |
Last 6 Months |
28.1% |
68 |
Last 12 Months |
9.7% |
76 |
Historical chartsINSTITUTIONAL STATISTICS
Analyst Consensus | Moderate Buy |
Institutional Ownership | 70.50% |
More Analyst RatingsQUICK FACTS
Location | 235 East 42nd Street NEW YORK NY 10017-5755 Phone: 212-7332323 Fax: 302-6555049 |
Web Site | http://www.pfizer.com |
Industry | Drug Manufacturers - Major |
Employees | 103,700 |
Exchange | NYSE |
FINANCIALS
| Last 12 Months | 5 Year Growth |
Sales |
67.4 Bil |
6.9% |
Income |
8.7 Bil |
-4.6% |
Dividend Rate |
0.88 |
-3.58% |
Dividend Yield |
3.90% |
4.90% |
More financialsFUNDAMENTAL DATA
Debt/Equity Ratio | 0.47 |
Gross Margin | 77.63% |
Net Profit Margin | 12.96% |
Total Shares Outstanding | 7.5 Bil |
Market Capitalization | 168.73 Bil |
Earnings/Share | 1.27 |
More financial ratiosEARNINGS ESTIMATES
Qtr(3/12) EPS Estimate |
0.56 |
FY(12/12) EPS Estimate |
2.26
|
Current P/E |
20.40 |
FY(12/13) EPS Estimate |
2.36
|
Forward P/E |
9.49 |
Next Earnings Release: N/A
More analyst estimates
OWNERSHIP INFORMATION
Shares Outstanding |
7.54 Bil |
Institutional Ownership (%) | 70.50 |
Top 10 Institutions (%) | 21.60 |
Mutual Fund Ownership (%) | 1.73 |
5%/Insider Ownership (%) | 26.00 |
Float (%) | 74.00 |
OWNERSHIP ACTIVITY
Description | # of Holders | Shares |
Total Positions |
1,618 | 5,313,455,616 |
New Positions | 122 | 0 |
Soldout Positions | 226 | 0 |
Net Position Change | -279 | -242,229,760 |
Buyers | 697 | 226,752,912 |
Sellers | 976 | -468,982,688 |
EARNINGS ESTIMATES
| Qtr(3/12) | Qtr(6/12) | FY(12/12) | FY(12/13) |
---|
Average Estimate | 0.56 | 0.56 | 2.26 | 2.36 |
Number of Analysts | 13 | 13 | 18 | 16 |
High Estimate | 0.61 | 0.59 | 2.31 | 2.50 |
Low Estimate | 0.53 | 0.52 | 2.20 | 2.24 |
Year Ago EPS | 0.60 | 0.60 | 2.31 | 2.26 |
Growth Rate | -6.15% | -6.03% | -2.16% | +4.23% |
Financial data in U.S. dollars
EARNINGS SURPRISE
| (12/10) | (3/11) | (6/11) | (9/11) | (12/11) |
---|
Estimate | 0.46 | 0.58 | 0.59 | 0.56 | 0.47 |
Actual | 0.47 | 0.60 | 0.60 | 0.62 | 0.50 |
Difference | 0.01 | 0.02 | 0.01 | 0.06 | 0.03 |
% Change | +2.17% | +3.45% | +1.69% | +10.71% | +6.38% |
Financial data in U.S. dollars
EARNINGS GROWTH RATES
| Last 5 Years | FY 2012 | FY 2013 | Next 5 Years | 12 P/E |
---|
Company | +2.00% | -2.20% | +4.20% | +3.80% | 10.00 |
Industry | +11.30% | +1.20% | +5.00% | +5.70% | 13.60 |
S&P 500 | NA | NA | +5.80% | NA | 14.60 |
CONSENSUS EPS TREND
| Qtr(3/12) | Qtr(6/12) | FY(12/12) | FY(12/13) |
---|
Current Estimate | 0.56 | 0.56 | 2.26 | 2.36 |
7 Days Ago | 0.56 | 0.56 | 2.26 | 2.36 |
30 Days Ago | 0.56 | 0.56 | 2.26 | 2.36 |
60 Days Ago | 0.56 | 0.57 | 2.26 | 2.35 |
90 Days Ago | 0.57 | 0.57 | 2.30 | 2.39 |
Financial data in U.S. dollars
Zacks average brokerage recommendation is Moderate Buy.
ANALYST RATINGS
Recommendations | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
---|
Strong Buy | 13 | 13 | 13 | 13 |
Moderate Buy | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 |
Moderate Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Mean Rec. | 1.32 | 1.32 | 1.32 | 1.32 |
1.0 = | Strong Buy |
1.1 thru 2.0 = | Moderate Buy |
2.1 thru 3.0 = | Hold |
3.1 thru 4.0 = | Moderate Sell |
4.1 thru 5.0 = | Strong Sell |
FINANCIAL HIGHLIGHTS
Sales | 67.43 Bil | Revenue/Share | 8.57 |
Income | 8.70 Bil | Earnings/Share | 1.27 |
Net Profit Margin | 12.96% | Book Value/Share | 10.85 |
Return on Equity | 10.24% | Dividend Rate | 0.88 |
Debt/Equity Ratio | 0.47 | Payout Ratio | 71.00% |
REVENUE - QUARTERLY RESULTS (IN MILLIONS) | FY (12/11) | FY (12/10) | FY (12/09) |
---|
1st Qtr | 16,502.0 | 16,576.0 | 10,867.0 | 2nd Qtr | 16,984.0 | 17,132.0 | 10,984.0 | 3rd Qtr | 17,193.0 | 15,995.0 | 11,621.0 | 4th Qtr | 16,746.0 | 17,354.0 | 16,537.0 | Total | 67,425.0 | 67,057.0 | 50,009.0 |
QTR. OVER QTR. EPS GROWTH RATE | FY (12/11) | FY (12/10) | FY (12/09) |
---|
1st Qtr | -22% | 150% | --- | 2nd Qtr | 18% | 24% | -17% | 3rd Qtr | 45% | -65% | 26% | 4th Qtr | -60% | 227% | -77% |
| EARNINGS PER SHARE - QUARTERLY RESULTS | FY (12/11) | FY (12/10) | FY (12/09) |
---|
1st Qtr | $0.28 | $0.25 | $0.41 | 2nd Qtr | $0.33 | $0.31 | $0.34 | 3rd Qtr | $0.48 | $0.11 | $0.43 | 4th Qtr | $0.19 | $0.36 | $0.10 | Total | $1.28 | $1.03 | $1.28 |
YR. OVER YR. EPS GROWTH RATE | FY (12/11) | FY (12/10) |
---|
1st Qtr | 12% | -39% | 2nd Qtr | 6% | -9% | 3rd Qtr | 336% | -74% | 4th Qtr | -47% | 260% |
|
Financial data in U.S. dollars
Financial data in U.S. dollars
Growth Rates % | Company | Industry | S&P 500 |
---|
Sales (Qtr vs year ago qtr) | -3.50 | 2.00 | 10.00 |
Net Income (YTD vs YTD) | NA | NA | NA |
Net Income (Qtr vs year ago qtr) | -48.60 | 77.70 | 47.80 |
Sales (5-Year Annual Avg.) | 6.87 | 6.77 | 8.14 |
Net Income (5-Year Annual Avg.) | -4.63 | 5.76 | 8.17 |
Dividends (5-Year Annual Avg.) | -3.58 | 8.23 | 5.00 |
Price Ratios | Company | Industry | S&P 500 |
---|
Current P/E Ratio | 20.4 | 16.3 | 39.1 |
P/E Ratio 5-Year High | NA | 20.5 | 13.9 |
P/E Ratio 5-Year Low | NA | 3.9 | 3.1 |
Price/Sales Ratio | 2.52 | 3.19 | 2.34 |
Price/Book Value | 2.08 | 4.34 | 12.43 |
Price/Cash Flow Ratio | 9.60 | 10.40 | 12.40 |
Profit Margins % | Company | Industry | S&P 500 |
---|
Gross Margin | 77.6 | 69.7 | 39.4 |
Pre-Tax Margin | 18.9 | 8.4 | 17.8 |
Net Profit Margin | 13.0 | 16.2 | 13.0 |
5Yr Gross Margin (5-Year Avg.) | 79.1 | 70.7 | 39.5 |
5Yr PreTax Margin (5-Year Avg.) | 18.4 | 7.9 | 15.8 |
5Yr Net Profit Margin (5-Year Avg.) | 14.9 | 3.4 | 11.4 |
Financial Condition | Company | Industry | S&P 500 |
---|
Debt/Equity Ratio | 0.47 | 0.92 | 2.04 |
Current Ratio | 2.1 | 1.7 | 1.4 |
Quick Ratio | 1.8 | 1.4 | 0.9 |
Interest Coverage | 11.4 | 30.8 | 33.1 |
Leverage Ratio | 2.3 | 2.9 | 5.7 |
Book Value/Share | 10.85 | 16.26 | 27.32 |
Investment Returns % | Company | Industry | S&P 500 |
---|
Return On Equity | 10.2 | 59.5 | 28.2 |
Return On Assets | 4.6 | 9.2 | 8.7 |
Return On Capital | 5.4 | 12.4 | 11.6 |
Return On Equity (5-Year Avg.) | 11.0 | 22.8 | 24.6 |
Return On Assets (5-Year Avg.) | 5.3 | 9.7 | 8.1 |
Return On Capital (5-Year Avg.) | 6.5 | 13.0 | 10.9 |
Management Efficiency | Company | Industry | S&P 500 |
---|
Income/Employee | 84,272 | 89,236 | 131,446 |
Revenue/Employee | 650,193 | 540,582 | 1 Mil |
Receivable Turnover | 5.0 | 5.7 | 14.9 |
Inventory Turnover | 1.9 | 2.9 | 12.6 |
Asset Turnover | 0.4 | 0.6 | 0.8 |
| Avg P/E | Price/ Sales | Price/ Book | Net Profit Margin (%) |
---|
12/11 | 17.70 | 2.53 | 1.99 | 12.9 |
12/10 | 16.50 | 2.11 | 1.60 | 12.2 |
12/09 | 13.10 | 2.60 | 1.63 | 17.3 |
12/08 | 16.20 | 2.48 | 2.08 | 16.6 |
12/07 | 21.30 | 3.26 | 2.36 | 17.0 |
12/06 | 17.00 | 3.89 | 2.59 | 22.8 |
12/05 | 24.80 | 3.65 | 2.61 | 16.0 |
12/04 | 22.90 | 4.18 | 2.94 | 22.3 |
12/03 | 142.80 | 5.75 | 4.12 | 3.6 |
12/02 | 23.80 | 5.91 | 9.44 | 28.4 |
| Book Value/ Share | Debt/ Equity | Return on Equity (%) | Return on Assets (%) | Interest Coverage |
---|
12/11 | $10.85 | 0.47 | 10.6 | 4.6 | 7.6 |
12/10 | $10.96 | 0.50 | 9.3 | 4.2 | 5.2 |
12/09 | $11.15 | 0.54 | 9.5 | 4.0 | 8.7 |
12/08 | $8.53 | 0.30 | 13.9 | 7.2 | 18.8 |
12/07 | $9.62 | 0.20 | 12.6 | 7.1 | 23.4 |
12/06 | $10.02 | 0.11 | 15.4 | 9.5 | 26.7 |
12/05 | $8.93 | 0.27 | 11.6 | 6.5 | 22.9 |
12/04 | $9.14 | 0.27 | 16.0 | 8.9 | 38.6 |
12/03 | $8.57 | 0.22 | 2.5 | 1.4 | 12.0 |
12/02 | $3.24 | 0.59 | 45.9 | 19.8 | 46.9 |
Industry: Drug Manufacturers - Major
Computed ratios are based on latest 12 months' results.
Annual Income Statement
Quarterly Income Statement
Annual Balance Sheet
Quarterly Balance Sheet
Annual Cash flow Statement
Quarterly Cash flow Statement
Ten Year Summary